The Latest Breaking News from CMS

Drugmakers will be required to pay Medicare back for price increases that outpace inflation. The industry is expected to put up a fight over implementation.

WASHINGTON — The Biden administration’s plan to unwind the public health emergency tied to the COVID-19 pandemic will spur a whirlwind of changes related to telehealth, Medicaid, pharmaceuticals and other priorities.

This month, the Food and Drug Administration approved a new drug, lecanemab, for the treatment of Alzheimer’s disease. The drug, sold under the brand name Leqembi, was developed by Japanese pharmaceutical company Eisai and will be marketed commercially in partnership with American pharmaceutical company Biogen. Biogen, notably, is the maker…

Previously secret government audits reveal millions of dollars in overpayments to Medicare Advantage health plans

Panel of experts at Insider breakfast event states that existing oil and gas industry must be supported in move to renewables

A treatment that improves Alzheimer’s disease would be a great advance, but Leqembi (lecanemab), which recently received accelerated approval from the FDA, is not that drug. Yes, lecanemab slows decline to an extent detectable on a test, but not to an extent that a relative or caretaker would notice. This…

The federal government says it will begin a targeted crackdown on nursing homes’ abuse of antipsychotic drugs and misdiagnoses of schizophrenia in patients

A new survey of the financial and professional services sector finds most firms are not enforcing minimum number of office days

The measures are aimed at stopping perpetrators from using child maintenance as a form of ongoing financial abuse and control